Table 2.
Oncological characteristics (n = 37).
| N (%) | |
|---|---|
| Histological types | |
| Ductal carcinoma invasive (DCI) | 23 (62.1%) |
| Ductal carcinoma in situ (DCIS) | 6 (16.2%) |
| Lobular carcinoma invasive (LCI) | 5 (13.5%) |
| Combined breast cancer * | 2 (5.4%) |
| Other | 1 (2.7%) |
| Hormonal receptors | 25 (67.5%) |
| HER 2+ | 23 (62%) |
| Tumor size according to TNM classification | |
| Tis | 4 (10.8%) |
| T1 | 17 (45.9%) |
| T2 | 11 (29.7%) |
| T3 | 3 (8.1%) |
| T4 | 2 (5.4%) |
| Axillary lymph node disease | 16 (43.2%) |
| Visceral metastases | 3 (8.1%) |
| Chemotherapy | 21 (56.7%) |
| Radiotherapy | 19 (51.3%) |
| Hormotherapy | 21 (56.7%) |
| Axillary node management | |
| No | 1 (2.7%) |
| Sentinel node | 15 (40.5%) |
| Axillary Lymph node Dissection | 21 (56.7%) |
Continuous data are presented as average (standard deviation). Categorial data are presented as absolute numbers (percentage). * Combined breast cancer: DCI + LCI; Tis: ductal carcinoma in situ. TNM: EPU Breast Diseases 2018.